{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:26:09Z","timestamp":1778261169245,"version":"3.51.4"},"reference-count":65,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"19","license":[{"start":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:00:00Z","timestamp":1620950400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Sintilimab is a novel programmed cell death receptor-1 (PD-1) inhibitor approved in the treatment of classical Hodgkin's lymphoma and undergoing clinical trials for various malignancies. As a PD-1 inhibitor, sintilimab is known to cause autoimmune adverse events similar to other PD-1 inhibitors. Diabetic ketoacidosis (DKA) is a rare but severe adverse event of this therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>We report a case of a 59-year-old man who developed DKA after 5 doses of sintilimab for small cell lung cancer. His fasting glycemia level was 14.07\u200ammol\/L, urine ketone bodies were 4+, arterial blood pH was 7.271, bicarbonate was 12.3\u200ammol\/L, and glycated hemoglobin (HbA1c) was 7.4%. Extended investigations revealed that fasting C-peptide was undetectable (&lt;0.003\u200anmol\/L).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>These laboratory investigations supported the diagnosis of fulminant type 1 diabetes mellitus, but no \u03b2-cell related antibodies were positive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>After remission of DKA, he was treated with insulin therapy to acquire a normalization of glycemia and the disappearance of symptoms.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Sintilimab was withheld after 6 cycles and was converted to durvalumab to sustain the therapeutic effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>This case and associated literature review illustrate the importance of educating and monitoring patients who start PD-1 inhibitor therapy regarding this potentially life-threatening complication.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000025795","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T19:58:48Z","timestamp":1620763128000},"page":"e25795","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Sintilimab induced diabetic ketoacidosis in a patient with small cell lung cancer"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4043-3404","authenticated-orcid":false,"given":"Xiaofei","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Libo","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, The Third People's Hospital of Chengdu, The Second Affiliated Hospital of Chengdu, Chongqing Medical University, Chengdu, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,5,14]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","article-title":"A paradigm shift in cancer immunotherapy: from enhancement to normalization","volume":"175","author":"Sanmamed","year":"2018","journal-title":"Cell"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/jdi.12024","article-title":"Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012)","volume":"3","author":"Imagawa","year":"2012","journal-title":"J Diabetes Investig"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.3389\/fimmu.2020.02076","article-title":"Sintilimab-induced autoimmune diabetes in a patient with the anti-tumor effect of partial regression","volume":"11","author":"Wen","year":"2020","journal-title":"Front Immunol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","article-title":"Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy","volume":"38","author":"Hughes","year":"2015","journal-title":"Diabetes Care"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2337\/dc15-1331","article-title":"Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes","volume":"38","author":"Gaudy","year":"2015","journal-title":"Diabetes Care"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.2337\/dc15-0889","article-title":"Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes","volume":"38","author":"Mellati","year":"2015","journal-title":"Diabetes Care"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","article-title":"Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report","volume":"64","author":"Martin-Liberal","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1620\/tjem.239.155","article-title":"An anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes","volume":"239","author":"Miyoshi","year":"2016","journal-title":"Tohoku J Exp Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"303","DOI":"10.14310\/horm.2002.1656","article-title":"A case of multiple immune toxicities from Ipilimumab and pembrolizumab treatment","volume":"15","author":"Humayun","year":"2016","journal-title":"Hormones (Athens)"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"bcr2016217454","DOI":"10.1136\/bcr-2016-217454","article-title":"Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma","volume":"2016","author":"Aleksova","year":"2016","journal-title":"BMJ Case Rep"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","article-title":"Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy","volume":"4","author":"Lowe","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"066","DOI":"10.23937\/2378-3419\/3\/4\/1066","article-title":"Rapid development of type 1 diabetes mellitus after initiation of anti-PD-1 therapy","volume":"3","author":"Shah","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00592-016-0872-y","article-title":"Anti-programmed cell death 1 therapy triggering diabetic ketoacidosis and fulminant type 1 diabetes","volume":"53","author":"Kong","year":"2016","journal-title":"Acta Diabetol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11523-017-0480-y","article-title":"Anti-PD-L1 atezolizumab-induced autoimmune diabetes: a case report and review of the literature","volume":"12","author":"Hickmott","year":"2017","journal-title":"Target Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40425-017-0245-2","article-title":"Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer","volume":"5","author":"Godwin","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2217\/imt-2017-0020","article-title":"A case of fulminant type 1 diabetes following anti-PD1 immunotherapy in a genetically susceptible patient","volume":"9","author":"Araujo","year":"2017","journal-title":"Immunotherapy"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000456540","article-title":"Autoimmune diabetes and thyroiditis complicating treatment with nivolumab","volume":"10","author":"Li","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","article-title":"Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review","volume":"66","author":"Gauci","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/imt-2017-0042","article-title":"Case report: pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma","volume":"9","author":"Smith-Cohn","year":"2017","journal-title":"Immunotherapy"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke","year":"2017","journal-title":"Case Rep Oncol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/1346-8138.13486","article-title":"Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient","volume":"44","author":"Teramoto","year":"2017","journal-title":"J Dermatol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.diabet.2016.05.007","article-title":"Autoimmune diabetes superimposed on type 2 diabetes in a patient initiated on immunotherapy for lung cancer","volume":"43","author":"Alhusseini","year":"2017","journal-title":"Diabetes Metab"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4158\/EP161410.CR","article-title":"Development of type 1 diabetes after cancer immunotherapy","volume":"3","author":"Hao","year":"2017","journal-title":"AACE Clinical Case Rep"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2340\/00015555-2504","article-title":"Acute lower limb ischaemia and diabetes in a patient treated with anti-PD1 monoclonal antibody for metastatic melanoma","volume":"97","author":"Thoreau","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jtho.2016.12.015","article-title":"Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer","volume":"12","author":"Usui","year":"2017","journal-title":"J Thorac Oncol"},{"key":"R31-20250504","first-page":"49","article-title":"Autoimmune diabetes presented with diabetic ketoacidosis induced by immunotherapy in an adult with melanoma","volume":"169","author":"Alzenaidi","year":"2017","journal-title":"J La State Med Soc"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/CJI.0000000000000173","article-title":"Diabetic ketoacidosis as an immune-related adverse event from pembrolizumab in non-small cell lung cancer","volume":"40","author":"Leonardi","year":"2017","journal-title":"J Immunother"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/pcmr.12607","article-title":"A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity","volume":"30","author":"Chan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.diabres.2017.07.036","article-title":"Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells","volume":"133","author":"Iijima","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-017-0303-9","article-title":"Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma","volume":"5","author":"Changizzadeh","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"bcr2017220415","DOI":"10.1136\/bcr-2017-220415","article-title":"Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies","volume":"2017","author":"Way","year":"2017","journal-title":"BMJ Case Rep"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"06","DOI":"10.1186\/s40164-018-0098-5","article-title":"Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report","volume":"7","author":"Meyers","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"R38-20250504","first-page":"17","article-title":"New-onset insulin-dependent diabetes due to nivolumab","volume":"2018","author":"Zaied","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R39-20250504","first-page":"8981375","article-title":"Fulminant diabetes in a patient with advanced melanoma on nivolumab","volume":"2018","author":"Chokr","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"R40-20250504","first-page":"18","article-title":"Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy","volume":"2018","author":"Lee","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R42-20250504","first-page":"e12907\u20139","article-title":"Anti-PD-1 pembrolizumab induced autoimmune diabetes in Chinese patient: a case report","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"bcr2017220999","DOI":"10.1136\/bcr-2017-220999","article-title":"New onset diabetes after nivolumab treatment","volume":"2018","author":"Capitao","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R45-20250504","first-page":"18","article-title":"Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis","volume":"2018","author":"Tzoulis","year":"2018","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CMR.0000000000000418","article-title":"Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma","volume":"28","author":"Takahashi","year":"2018","journal-title":"Melanoma Res"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","article-title":"Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype","volume":"56","author":"Marchand","year":"2019","journal-title":"Acta Diabetol"},{"key":"R48-20250504","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajem.2018.10.040","article-title":"Diabetic ketoacidosis induced by a single dose of pembrolizumab","volume":"37","author":"Maamari","year":"2019","journal-title":"Am J Emerg Med"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1210\/js.2018-00366","article-title":"Immune checkpoint blockade anti-PD-L1 as a trigger for autoimmune polyendocrine syndrome","volume":"3","author":"Lanzolla","year":"2019","journal-title":"J Endocr Soc"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"e229568","DOI":"10.1136\/bcr-2019-229568","article-title":"Rapid onset type-1 diabetes and diabetic ketoacidosis secondary to nivolumab immunotherapy: a review of existing literature","volume":"12","author":"Abdullah","year":"2019","journal-title":"BMJ Case Rep"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"5499","DOI":"10.1210\/jc.2019-00423","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3747\/co.26.4130","article-title":"A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma","volume":"26","author":"Sakaguchi","year":"2019","journal-title":"Curr Oncol"},{"key":"R53-20250504","first-page":"18","article-title":"A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma","volume":"2019","author":"Hakami","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12902-019-0467-z","article-title":"Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports","volume":"19","author":"Zezza","year":"2019","journal-title":"BMC Endocr Disord"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fendo.2019.00352","article-title":"Atezolizumab-induced autoimmune diabetes in a patient with metastatic lung cancer","volume":"10","author":"Sothornwit","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R56-20250504","first-page":"19","article-title":"Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism","volume":"2019","author":"Patel","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"R58-20250504","first-page":"19","article-title":"Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment","volume":"2019","author":"Mengibar","year":"2019","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1177\/1078155219841116","article-title":"Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event","volume":"26","author":"Yilmaz","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.21037\/tlcr.2020.03.05","article-title":"Anti PD-1 monoclonal antibody induced autoimmune diabetes mellitus: a case report and brief review","volume":"9","author":"Li","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R61-20250504","first-page":"19","article-title":"Pembrolizumab-induced fulminant type 1 diabetes with C-peptide persistence at first referral","volume":"2020","author":"Kusuki","year":"2020","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fendo.2020.00014","article-title":"Immune checkpoint inhibitor-induced diabetic ketoacidosis: a report of four cases and literature review","volume":"11","author":"Hong","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R63-20250504","first-page":"8671530","article-title":"Critical care admission of an HIV patient with diabetic ketoacidosis secondary to pembrolizumab","volume":"2020","author":"Cuenca","year":"2020","journal-title":"Case Rep Crit Care"},{"issue":"(Suppl 2)","key":"R64-20250504","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/diabetes.54.suppl_2.S52","article-title":"Autoantibodies in diabetes","volume":"54","author":"Pihoker","year":"2005","journal-title":"Diabetes"},{"key":"R65-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.21037\/tlcr.2019.12.17","article-title":"Endocrine adverse events related to immune-oncology agents: retrospective experience of a single institution","volume":"9","author":"Espana","year":"2020","journal-title":"Transl Lung Cancer Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025795","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:43:09Z","timestamp":1746337389000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000025795"}},"subtitle":["A case report and literature review"],"short-title":[],"issued":{"date-parts":[[2021,5,14]]},"references-count":65,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000025795","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,14]]},"assertion":[{"value":"2020-12-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}